阿司匹林与依诺肝素对髋或膝关节置换术后症状性静脉血栓栓塞的影响:CRISTAL随机试验
CRISTAL为澳大利亚31家医院的集群随机交叉注册嵌套试验,纳入9711例≥18岁行全髋或全膝关节置换患者(阿司匹林组5675例,依诺肝素组4036例),比较阿司匹林100 mg/d与依诺肝素40 mg/d(THA后35天、TKA后14天)对90天内症状性VTE的预防效果,非劣效界值1%。结果显示阿司匹林组症状性VTE发生率3.45%,依诺肝素组1.82%,估计差值1.97%(95%CI 0.54%-3.41%),未达到非劣效标准,依诺肝素显著更优(P=.007)。6项次要结局中依诺肝素组无一显著优于阿司匹林组。
要点
- 在骨关节炎行THA或TKA患者中,阿司匹林100 mg/d较依诺肝素40 mg/d显著增加90天内症状性VTE:3.45% vs 1.82%(差值1.97%,95%CI 0.54%-3.41%,P=.007)。
- 非劣效界值为1%,阿司匹林组差值95%CI下限0.54%未低于1%,非劣效未成立。
- 90天内共256例症状性VTE,包括肺栓塞79例、膝上DVT 18例、膝下DVT 174例。
- 6项次要结局(包括死亡和大出血)中,依诺肝素组无一显著优于阿司匹林组。
- 因中期分析达到停止规则,研究提前终止,实际入组9711例(预设15562例的62%),9203例(95%)完成试验。
适用人群与场景
- 澳大利亚31家年手术量大于250例的医院中,年龄≥18岁行全髋或全膝关节置换的患者。
- 排除术前正在接受抗凝治疗或对任一研究药物有禁忌证的患者。
诊断标准与关键阈值
- 主要结局为90天内症状性VTE,包括肺栓塞和深静脉血栓(膝上或膝下)。
- 非劣效界值为1%。
处置流程与药物剂量
- 阿司匹林100 mg/d,全髋关节置换后使用35天,全膝关节置换后使用14天。
- 依诺肝素40 mg/d,全髋关节置换后使用35天,全膝关节置换后使用14天。
研究设计与关键结果
- 集群随机交叉注册嵌套试验,澳大利亚31家医院,9711例患者(阿司匹林组5675例,依诺肝素组4036例),中位年龄68岁,女性56.8%。
- 90天内症状性VTE:阿司匹林组3.45% vs 依诺肝素组1.82%,估计差值1.97%(95%CI 0.54%-3.41%),未达到非劣效标准,依诺肝素显著更优(P=.007)。
- 90天内共256例症状性VTE:肺栓塞79例,膝上DVT 18例,膝下DVT 174例。
- 6项次要结局(包括90天内死亡和大出血)中,依诺肝素组无一显著优于阿司匹林组。
- 因中期分析达到停止规则提前终止,入组9711例(预设15562例的62%),9203例(95%)完成试验。
证据类型、等级与局限
- 随机对照试验(集群随机交叉设计),非劣效检验。
- 局限:因中期分析达到停止规则提前终止,实际入组9711例,为预设15562例的62%。
对床旁实践的改变
- 作者结论:在因骨关节炎行髋或膝关节置换的患者中,与依诺肝素相比,阿司匹林导致90天内症状性VTE(膝下或膝上DVT或肺栓塞)发生率显著更高。
- 作者指出这些发现可能需结合成本效果分析来解读。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: There remains a lack of randomized trials investigating aspirin monotherapy for symptomatic venous thromboembolism (VTE) prophylaxis following total hip arthroplasty (THA) or total knee arthroplasty (TKA).
OBJECTIVE: To determine whether aspirin was noninferior to enoxaparin in preventing symptomatic VTE after THA or TKA.
DESIGN, SETTING, AND PARTICIPANTS: Cluster-randomized, crossover, registry-nested trial across 31 hospitals in Australia. Clusters were hospitals performing greater than 250 THA or TKA procedures annually. Patients (aged ≥18 years) undergoing hip or knee arthroplasty procedures were enrolled at each hospital. Patients receiving preoperative anticoagulation or who had a medical contraindication to either study drug were excluded. A total of 9711 eligible patients were enrolled (5675 in the aspirin group and 4036 in the enoxaparin group) between April 20, 2019, and December 18, 2020. Final follow-up occurred on August 14, 2021.
INTERVENTIONS: Hospitals were randomized to administer aspirin (100 mg/d) or enoxaparin (40 mg/d) for 35 days after THA and for 14 days after TKA. Crossover occurred after the patient enrollment target had been met for the first group. All 31 hospitals were initially randomized and 16 crossed over prior to trial cessation.
MAIN OUTCOMES AND MEASURES: The primary outcome was symptomatic VTE within 90 days, including pulmonary embolism and deep venous thrombosis (DVT) (above or below the knee). The noninferiority margin was 1%. Six secondary outcomes are reported, including death and major bleeding within 90 days. Analyses were performed by randomization group.
RESULTS: Enrollment was stopped after an interim analysis determined the stopping rule was met, with 9711 patients (median age, 68 years; 56.8% female) of the prespecified 15 562 enrolled (62%). Of these, 9203 (95%) completed the trial. Within 90 days of surgery, symptomatic VTE occurred in 256 patients, including pulmonary embolism (79 cases), above-knee DVT (18 cases), and below-knee DVT (174 cases). The symptomatic VTE rate in the aspirin group was 3.45% and in the enoxaparin group was 1.82% (estimated difference, 1.97%; 95% CI, 0.54%-3.41%). This failed to meet the criterion for noninferiority for aspirin and was significantly superior for enoxaparin (P = .007). Of 6 secondary outcomes, none were significantly better in the enoxaparin group compared with the aspirin group.
CONCLUSIONS AND RELEVANCE: Among patients undergoing hip or knee arthroplasty for osteoarthritis, aspirin compared with enoxaparin resulted in a significantly higher rate of symptomatic VTE within 90 days, defined as below- or above-knee DVT or pulmonary embolism. These findings may be informed by a cost-effectiveness analysis.
TRIAL REGISTRATION: ANZCTR Identifier: ACTRN12618001879257.
参考来源
- Sidhu VS, Kelly TL, Pratt N, et al. Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial. JAMA. 2022. PMID: 35997730. doi:10.1001/jama.2022.13416
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。